8 completed, 1 not yet recruiting, 1 recruiting. 10 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 8, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Migraine, With or Without Aura: new trials by email Literature Review of Migraine, With or Without Aura trials Research Report on Migraine, With or Without Aura
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults BR005-036C, Placebo - Migraine, With or Without Aura | Phase 2 / Phase 3 | Recruiting | Brise Pharmaceuticals Co., Ltd. | 2079 | 2026-09-30 | 2026-10-23 |
| Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults BR005-036C - Migraine, With or Without Aura | Phase 3 | Not yet recruiting | Brise Pharmaceuticals Co., Ltd. | 1000 | 2026-09-30 | 2026-09-25 |
| Trial in Adult Subjects With Acute Migraines Rimegepant, Placebo - Migraine, With or Without Aura | Phase 3 | Completed | Pfizer | 1811 | 2018-02-27 | 2023-02-16 |
| Open Label Safety Study in Acute Treatment of Migraine Rimegepant - Migraine, With or Without Aura | Phase 2 / Phase 3 | Completed | Pfizer | 3019 | 2017-08-30 | 2023-02-16 |
| Safety and Efficacy in Adult Subjects With Acute Migraines Rimegepant, Placebo - Migraine, With or Without Aura | Phase 3 | Completed | Pfizer | 1499 | 2017-07-27 | 2023-02-16 |
| Safety and Efficacy Study in Adult Subjects With Acute Migraines Rimegepant, Placebo - Migraine, With or Without Aura | Phase 3 | Completed | Pfizer | 1485 | 2017-07-18 | 2023-02-16 |
| An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant, Usual Care - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1254 | 2016-09-13 | 2019-08-28 |
| Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Atogepant, Placebo-matching Atogepant - Migraine, With or Without Aura | Phase 2 / Phase 3 | Completed | Allergan | 834 | 2016-09-06 | 2018-12-06 |
| Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1686 | 2016-08-26 | 2019-03-19 |
| Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1672 | 2016-07-22 | 2019-01-03 |
Migraine Disorders (10)
Brain Diseases (10) · Central Nervous System Diseases (10) · Headache Disorders (10) · Headache Disorders, Primary (10) · Nervous System Diseases (10)
rimegepant sulfate (4) · ubrogepant (3) · atogepant (1)
Allergan (4) · Pfizer (4) · Brise Pharmaceuticals Co., Ltd. (2)
United States (8) · China (2)
Adele Thorpe (3) · Joel Trugman, MD (1)
PMID 34874514, PMID 36125279, PMID 36739511, PMID 39982105, PMID 41652666, PMID 42839212, PMID 33241721, PMID 33608814, PMID 33874756, PMID 35468729, PMID 31291516, PMID 31311674, PMID 31742631, PMID 31800988, PMID 31932515, PMID 32822633, PMID 34455556, PMID 35038983, PMID 35977836, PMID 38462625, PMID 38659334, PMID 38764606, PMID 38985436, PMID 39070853, PMID 39520634, PMID 39648629, PMID 40629887